Comment on

• Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

  Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-DHF Investigators. Edelmann F, et al. JAMA. 2013 Feb 27;309(8):781-91. doi: 10.1001/jama.2013.905. JAMA. 2013. PMID: 23443441 Clinical Trial.
• Aldosterone inhibition in patients with heart failure with preserved ejection fraction.

  Neil CJ, Singh S, Frenneaux M. Neil CJ, et al. JAMA. 2013 Jul 10;310(2):204. doi: 10.1001/jama.2013.7970. JAMA. 2013. PMID: 23839756 No abstract available.
• Aldosterone inhibition in patients with heart failure with preserved ejection fraction.

  Milan A, Abram S, Veglio F. Milan A, et al. JAMA. 2013 Jul 10;310(2):204-5. doi: 10.1001/jama.2013.7973. JAMA. 2013. PMID: 23839757 No abstract available.
• Aldosterone inhibition in patients with heart failure with preserved ejection fraction.

  Lund LH, Ståhlberg M. Lund LH, et al. JAMA. 2013 Jul 10;310(2):205. doi: 10.1001/jama.2013.7967. JAMA. 2013. PMID: 23839758 No abstract available.